Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism

BACKGROUND: Monoclonal antibodies blocking the programmed cell death-1 (PD-1) or its ligand (PD-L1) are a group of immune checkpoints inhibitors (ICIs) with proven antitumor efficacy. However, their use is complicated by immune-related adverse events (irAEs), including endocrine adverse events (eAEs...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaafar, Jaafar, Fernandez, Eugenio, Alwan, Heba, Philippe, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937198/
https://www.ncbi.nlm.nih.gov/pubmed/29739808
http://dx.doi.org/10.1530/EC-18-0079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937198/
https://www.ncbi.nlm.nih.gov/pubmed/29739808
http://dx.doi.org/10.1530/EC-18-0079

Ejemplares similares